Role of itraconazole metabolites in CYP3A4 inhibition

Drug Metabolism and Disposition : the Biological Fate of Chemicals
N IsoherranenK E Thummel

Abstract

Itraconazole (ITZ) is a potent inhibitor of CYP3A in vivo. However, unbound plasma concentrations of ITZ are much lower than its reported in vitro Ki, and no clinically significant interactions would be expected based on a reversible mechanism of inhibition. The purpose of this study was to evaluate the reasons for the in vitro-in vivo discrepancy. The metabolism of ITZ by CYP3A4 was studied. Three metabolites were detected: hydroxy-itraconazole (OH-ITZ), a known in vivo metabolite of ITZ, and two new metabolites: keto-itraconazole (keto-ITZ) and N-desalkyl-itraconazole (ND-ITZ). OHITZ and keto-ITZ were also substrates of CYP3A4. Using a substrate depletion kinetic approach for parameter determination, ITZ exhibited an unbound K(m) of 3.9 nM and an intrinsic clearance (CLint) of 69.3 ml.min(-1).nmol CYP3A4(-1). The respective unbound Km values for OH-ITZ and keto-ITZ were 27 nM and 1.4 nM and the CLint values were 19.8 and 62.5 ml.min(-1).nmol CYP3A4(-1). Inhibition of CYP3A4 by ITZ, OH-ITZ, keto-ITZ, and ND-ITZ was evaluated using hydroxylation of midazolam as a probe reaction. Both ITZ and OH-ITZ were competitive inhibitors of CYP3A4, with unbound Ki (1.3 nM for ITZ and 14.4 nM for OH-ITZ) close to their respective Km. ITZ, O...Continue Reading

References

Jan 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R M TuckerD A Stevens
Jan 1, 1989·Mycoses·J HeykantsG Cauwenbergh
Sep 1, 1988·Antimicrobial Agents and Chemotherapy·T C HardinJ G Kuhn
Jul 1, 1984·Journal of Medicinal Chemistry·J HeeresJ Van Cutsem
Oct 1, 1993·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M BonayE Autret
Oct 1, 1993·Clinical Pharmacokinetics·M Schäfer-Korting
Apr 1, 1993·Antimicrobial Agents and Chemotherapy·J A BaroneV Van de Velde
Dec 1, 1995·Clinical Pharmacology and Therapeutics·M P DucharmeD J Edwards
Jul 1, 1996·Clinical Pharmacology and Therapeutics·P J Neuvonen, K M Jalava
Apr 29, 1998·Clinical Pharmacology and Therapeutics·P J NeuvonenK T Kivistö
Jan 13, 1999·Clinical Pharmacokinetics·J M Poirier, G Cheymol
Mar 27, 2001·Transplantation Proceedings·R BanerjeeN R Banner
Jun 18, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·R Scott Obach, Anne E Reed-Hagen
Jun 18, 2002·Molecular Pharmacology·Yvonne S LinKenneth E Thummel
Nov 16, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Thanh Huu TranDavid J Greenblatt
Jul 29, 2003·Therapeutic Drug Monitoring·Matthew J Cervelli, Graeme R Russ
Aug 6, 2003·Electrophoresis·Michael C Breadmore, Wolfgang Thormann

❮ Previous
Next ❯

Citations

Jul 12, 2008·Archives of Toxicology·Olavi PelkonenHannu Raunio
May 4, 2006·European Journal of Clinical Pharmacology·Tiina JaakkolaPertti J Neuvonen
Jul 8, 2009·Applied Biochemistry and Biotechnology·Sepuri Asha, Maravajhala Vidyavathi
Jan 8, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Takeshi AkiyoshiHisakazu Ohtani
Nov 23, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Chi-Chi PengNina Isoherranen
May 23, 2007·Antimicrobial Agents and Chemotherapy·Susan M Abdel-RahmanJeffrey L Blumer
Mar 28, 2012·Antimicrobial Agents and Chemotherapy·Rodrigo Moreira da SilvaMarta de Lana
Oct 6, 2005·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Toshiro NiwaAkira Takagi
Jun 7, 2006·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Jacques TurgeonVéronique Michaud
Jan 1, 2014·The Journal of Antimicrobial Chemotherapy·H Ruth AshbeeWilliam W Hope
Feb 5, 2010·Journal of Toxicology·Nhareet SomchitZainul Amiruddin Zakaria
Aug 17, 2012·Journal of Microencapsulation·Sherief EssaPatrice Hildgen
Dec 20, 2011·Expert Opinion on Drug Metabolism & Toxicology·Gopal KrishnaEdward O'Mara
Mar 6, 2012·Expert Opinion on Drug Metabolism & Toxicology·Justin D Lutz, Nina Isoherranen
Mar 12, 2008·Expert Opinion on Drug Metabolism & Toxicology·Ping Zhao
Oct 15, 2011·Expert Opinion on Drug Metabolism & Toxicology·Paul O Gubbins
Oct 13, 2005·Expert Opinion on Pharmacotherapy·Paul O Gubbins, Jarrett R Amsden
Dec 7, 2007·Drug Metabolism Reviews·Yi-Tong LiuHong-Guang Xie
Jun 4, 2015·Journal of Pharmaceutical Sciences·Keith RiccardiLi Di
Jan 29, 2010·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·K Youdim, R Dodia
May 24, 2007·Journal of Pharmaceutical Sciences·Anshul GuptaQingcheng Mao
Jun 6, 2015·Journal of Clinical Pharmacology·Lichuan LiuSarah M Robertson
Jul 21, 2011·Clinica Chimica Acta; International Journal of Clinical Chemistry·Masatomo MiuraKenichi Sawada
Sep 24, 2005·Basic & Clinical Pharmacology & Toxicology·Lauri I KajosaariJanne T Backman
Apr 20, 2007·Journal of Clinical Pharmacology·Dominique Levêque, François Jehl
Sep 20, 2007·Pharmacoepidemiology and Drug Safety·Fanny DepontNicholas Moore

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.